Market News & Trends
BioLife Wins US Patent for Effervescent Oral Peptide Delivery Platform
BioLife has received a US patent for an effervescent tablet technology intended to enable oral delivery of peptide therapeutics, including GLP-1 receptor agonists used in…
AbbVie Strengthens Dermatology and Respiratory Pipeline With Apogee Acquisition
AbbVie has completed its acquisition of Apogee Therapeutics, adding a portfolio of long-acting antibody programs to its immunology and inflammation pipeline as the pharmaceutical company…
Lonza to Add Commercial Spray-Drying Capacity at Oregon Manufacturing Site
Constructed is expected to be completed on two new PSD-4 units that will expand Lonza’s US-based capacity for spray-dried dispersions, as drug developers face increasing…
Sandoz Plans Biosimilar Drug Substance Facility in Slovenia
Sandoz is planning a roughly $300 million investment in a new biosimilar drug substance manufacturing facility in Ljubljana, Slovenia, as the company moves to expand…
Xeris Taps medmix Pen Platform for Once-Weekly Levothyroxine Program
Xeris Pharmaceuticals has selected medmix’s Drug Delivery business, formerly known as Haselmeier, to provide the injection device for XP-8121, an investigational once-weekly subcutaneous formulation of…
Novartis Reassesses Del-desiran Program After Phase III DM1 Study Misses Primary Endpoint
Novartis is reassessing the development strategy for delpacibart etedesiran (del-desiran) after the investigational therapy failed to achieve the primary endpoint in a pivotal Phase III…
Allogenetics Secures $4.4M to Move Transplant Gene Therapy Toward Clinical Trials
German biotechnology company Allogenetics has raised approximately $4.4 million in a Pre-Series A financing round to advance an ex vivo gene therapy designed to reduce…
Rezera Advances Ruvonoflast Toward Phase 3 After Positive Phase 2 Inflammation Results
Clinical biotech Rezera (formerly NodThera Inc.) has reported positive topline findings from a Phase 2 study of ruvonoflast, an oral NLRP3 inhibitor being developed for…
Revvity Expands Human-Relevant Cell Model Capabilities With Human Cell Design Acquisition
Revvity is expanding its life sciences portfolio into human-relevant metabolic disease models through an agreement to acquire French biotechnology company Human Cell Design (HCD). The…
Athernal Bio Wins Innovate UK Grant for Early-Stage Leukemia Program
UK biotechnology company Athernal Bio has secured nearly $940,000 in non-dilutive funding from Innovate UK to advance an immunotherapy program aimed at preventing the development…
Evotec Begins Phase 1 Study of Orthopoxvirus Antibody Cocktail
Evotec has moved an investigational orthopoxvirus antibody program into the clinic, with its biologics development and manufacturing arm, Just – Evotec Biologics, initiating a Phase…
HeartBeat.bio, Cubase Bio Team Up to Map Cardiac Fibrosis in 3D
HeartBeat.bio AG and Cubase Bio are joining forces to develop a more detailed way of studying cardiovascular disease in human cardiac tissue, combining organoid models…
Onyx Scientific Invests More Than $2 Million to Expand API Manufacturing Capacity
Onyx Scientific is expanding its small molecule active pharmaceutical ingredient (API) manufacturing operations in Sunderland, UK, with an investment of more than $2 million aimed…
Ionis Receives Approval for First and Only Disease-Modifying treatment for AxD
The FDA has approved Ionis Pharmaceuticals’ ZANVASTRO™ (zilganersen) for the treatment of Alexander disease (AxD) in pediatric and adult patients. ZANVASTRO is the first and…
Smart Gel May Pave Way for Next-Gen Drug Delivery
University of Birmingham scientists have developed a new material that changes from a gel to a liquid-like state under ultraviolet light and can be rebuilt…
New Agreement Marks LifeCore’s Thirteenth Late-State Program to Generate Revenue
Lifecore Biomedical, Inc., a fully integrated injectables CDMO, has signed a new agreement to transfer a commercially marketed product to the company's pipeline. Under the…
3 Deaths From Experimental Cell Therapy; Novartis and BMS Pause CGT Trials
Reuters has reported that Novartis paused eight clinical trials of an experiment cell therapy, called rap-cel, targeting autoimmune and neurological disorders, after three patients died.…
Company’s First AI AI-Generated Design Goes Into Human Studies
BigHat Biosciences, a clinical-stage, AI-driven protein therapeutics platform company, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating…
Potential New Target Identified for Cancer Cachexia Therapy
Researchers at Helmholtz Munich, the Heidelberg Faculty of Medicine at Heidelberg University, the German Center for Diabetes Research (DZD) and the Technical University of Munich…
First Patient Dosed in Veloxis Pharmaceuticals Phase 2 Trial of Pegrizeprument for the Prevention of Organ Rejection in Kidney Transplant Recipients
Veloxis Pharmaceuticals, Inc., a global specialty pharmaceutical company part of Asahi Kasei Corporation, today announced that the first participant has been dosed in its Phase…
